PDF herunterladen
CC BY 4.0 · Synlett 2018; 29(02): 193-198
DOI: 10.1055/s-0036-1590920
letter
Copyright with the author

N1-Arylation of 1,4-Benzodiazepine-2-ones with Diaryliodonium Salts

Raysa Khan
a   Department of Chemistry, School of Life Sciences, University of Sussex, Falmer, BN19QJ, UK   eMail: j.spencer@sussex.ac.uk
,
Robert Felix
b   Tocris, Bio Techne, The Watkins Building, Atlantic Road, Bristol, BS11 9QD, UK
,
Paul D. Kemmitt
c   IMED Oncology, AstraZeneca, 310 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, UK
,
Simon J. Coles
d   UK National Crystallography Service, Chemistry, University of Southampton, Highfield, Southampton, SO17 1BJ, UK
,
Graham J. Tizzard
d   UK National Crystallography Service, Chemistry, University of Southampton, Highfield, Southampton, SO17 1BJ, UK
,
John Spencer  *
a   Department of Chemistry, School of Life Sciences, University of Sussex, Falmer, BN19QJ, UK   eMail: j.spencer@sussex.ac.uk
› InstitutsangabenR.K. is funded by an EPSRC/AZ funded PhD studentship (EP/M507568/1) with additional support from AstraZeneca [14550001 (SME)] and Tocris Biosciences. The EPSRC is also thanked for funding the UK ­National Crystallography Service
Weitere Informationen

Publikationsverlauf

Received: 13. Juli 2017

Accepted after revision: 06. September 2017

Publikationsdatum:
25. September 2017 (online)

   Lizenzen und Reprints Alle Artikel dieser Rubrik


Abstract

A library of N1-arylated 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-ones has been synthesized starting with unsymmetrical diaryliodonium salts using aqueous ammonia as a base. This can also be applied to a similar 1,3,4-benzotriazepin-2-one derivative.

Key words

benzodiazepines - N-arylation - iodonium salt - privileged scaffold - benzotriazepine

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/s-0036-1590920.
  • Supporting Information
 

  • References and Notes

  • 1 Filippakopoulos P. Qi J. Picaud S. Shen Y. Smith WB. Fedorov O. Morse EM. Keates T. Hickman TT. Felletar I. Philpott M. Munro S. McKeown MR. Wang Y. Christie AL. West N. Cameron MJ. Schwartz B. Heightman TD. La ThangueN. French CA. Wiest O. Kung AL. Knapp S. Bradner JE. Nature 2010; 468: 1067
    Crossref
  • 2 Field GF. Zally WJ. Sternbach LH. J. Am. Chem. Soc. 1967; 80: 332
  • 3 Ellmann JA. Acc. Chem. Res. 1996; 29: 132
    Crossref
  • 4 Nadin A. Sánchez LópezJ. M. Owens AP. Howells DM. Talbot AC. Harrison T. J. Org. Chem. 2003; 68: 2844
    CrossrefPubMed
  • 5 Baud MG. Lin-Shiao E. Cardote T. Tallant C. Pschibul A. Chan KH. Zengerle M. Garcia JR. Kwan TT. Ferguson FM. Ciulli A. Science 2014; 346: 638
    CrossrefPubMed
  • 6 Baud MG. Lin-Shiao E. Zengerle M. Tallant C. Ciulli A. J. Med. Chem. 2016; 59: 1492
    CrossrefPubMed
  • 7 Mirguet O. Gosmini R. Toum J. Clement CA. Barnathan M. Brusq JM. Mordaunt JE. Grimes RM. Crowe M. Pineau O. Ajakane M. Daugan A. Jeffrey P. Cutler L. Haynes AC. Smithers NN. Chung CW. Bamborough P. Uings IJ. Lewis A. Witherington J. Parr N. Prinjha RK. Nicodeme E. J. Med. Chem. 2013; 56: 7501
    CrossrefPubMed
  • 8 Liu JJ. Higgins B. Ju G. Kolinsky K. Luk KC. Packman K. Pizzolato G. Ren Y. Thakkar K. Tovar C. Zhang Z. Wovkulich PM. ACS Med. Chem. Lett. 2013; 4: 259
    CrossrefPubMed
  • 9 Evans B. Rittle K. Bock M. DiPardo R. Freidinger R. Whitter W. Lundell G. Veber D. Anderson P. Chang R. Lotti V. Cerino D. Chen T. Kling P. Kunkel K. Springer J. Hirshfield J. J. Med. Chem. 1988; 31: 2235
    Crossref
  • 10 Filippakopoulos P. Picaud S. Fedorov O. Keller M. Wrobel M. Morgenstern O. Bracher F. Knapp S. Bioorg. Med. Chem. 2012; 20: 1878
    CrossrefPubMed
  • 11 Smith SG. Sanchez R. Zhou M.-M. Chem. Biol. 2014; 573
  • 12 Filippakopoulos P. Knapp S. Nat. Rev. Drug Discovery 2014; 13: 337
    CrossrefPubMed
  • 13 Carter MC. Alber DG. Baxter RC. Bithell SK. Budworth J. Chubb A. Cockerill GS. Dowdell VC. L. Henderson EA. Keegan SJ. Kelsey RD. Lockyer MJ. Stables JN. Wilson LJ. Powell KL. J. Med. Chem. 2006; 49: 2311
    CrossrefPubMed
  • 14 Ghelani SM. Naliapara YT. J. Heterocycl. Chem. 2016; 53: 1795
    Crossref
  • 15 Abdelkafi H. Cintrat JC. Sci. Rep. 2015; 5: 12131
    CrossrefPubMed
  • 16 Kaur N. Int. J. Pharm. Biol. Sci. 2013; 485
  • 17 Hu X. Dong Y. Liu G. Mol. Diversity 2015; 19: 695
    CrossrefPubMed
  • 18 Spencer J. Rathnam R. Chowdhry B. Future Med. Chem. 2010; 2: 1441
    CrossrefPubMed
  • 19 Dzladulewlcz EK. Brown MC. Dunstan AR. Lee W. Said NB. Garratt PJ. Bioorg. Med. Chem. Lett. 1999; 9: 463
    Crossref
  • 20 McDonald I. Austin C. Buck I. Dunstone D. Gaffen J. Griffin E. Harper E. Hull R. Kalindjian S. Linney I. Low C. Patel D. Pether M. Raynor M. Roberts S. Shaxted M. Spencer J. Steel K. Sykes D. Wright P. Xun W. J. Med. Chem. 2007; 50: 4789
    CrossrefPubMed
  • 21 Cuny G. Bois-Choussy ML. Zhu J. J. Am. Chem. Soc. 2004; 126: 14475
    CrossrefPubMed
  • 22 Klapars A. Antilla JC. Huang X. Buchwald SL. J. Am. Chem. Soc. 2001; 123: 7727
    Crossref
  • 23 Talukdar D. Das G. Thakur S. Karak N. Thakur AJ. Catal. Commun. 2015; 59: 238
    Crossref
  • 24 Strittmatter SM. Nat. Med. 2014; 20: 590
    CrossrefPubMed
  • 25 Corsello SM. Bittker JA. Liu Z. Gould J. McCarren P. Hirschman JE. Johnston SE. Vrcic A. Wong B. Khan M. Asiedu J. Narayan R. Mader CC. Subramanian A. Golub TR. Nat. Med. 2017; 23: 405
    CrossrefPubMed
  • 26 Spencer J. Rathnam RP. Harvey AL. Clements CJ. Clark RL. Barrett MP. Wong PE. Male L. Coles SJ. Mackay SP. Bioorg. Med. Chem. 2011; 19: 1802
    CrossrefPubMed
  • 27 Clark RL. Clements CJ. Barrett MP. Mackay SP. Rathnam RP. Owusu-Dapaah G. Spencer J. Huggan JK. Bioorg. Med. Chem. 2012; 20: 6019
    CrossrefPubMed
  • 28 Spencer J. Chowdhry BZ. Mallet AI. Rathnam RP. Adatia T. Bashall A. Rominger F. Tetrahedron 2008; 64: 6082
    Crossref
  • 29 Khan R. Felix R. Kemmitt PD. Coles SJ. Day IJ. Tizzard GJ. Spencer J. Adv. Synth. Catal. 2016; 358: 98
    Crossref
  • 30 Merritt EA. Olofsson B. Angew. Chem. Int. Ed. 2009; 48: 9052
    Crossref
  • 31 Bielawski M. Aili D. Olofsson B. J. Org. Chem. 2008; 73: 4602
    CrossrefPubMed
    • 32a Yusubov MS. Maskaev AV. Zhdankin VV. ARKIVOC 2011; 370
  • 33 Ghosh R. Olofsson B. Org. Lett. 2014; 16: 1830
    Crossref
  • 34 Tinnis F. Stridfeldt E. Lundberg H. Adolfsson H. Olofsson B. Org. Lett. 2015; 17: 2688
    Crossref
  • 35 Malmgren J. Santoro S. Jalalian N. Himo F. Olofsson B. Chem. Eur. J. 2013; 19: 10334
    Crossref
  • 36 Gonda Z. Novak Z. Chem. Eur. J. 2015; 21: 16801
    Crossref
  • 37 Lanning M. Fletcher S. Future Med. Chem. 2013; 5: 2157
    CrossrefPubMed
  • 38 Azzarito V. Long K. Murphy NS. Wilson AJ. Nat. Chem. 2013; 5: 161
  • 39 Jalalian N. Ishikawa EE. Silva LF. Jr. Olofsson B. Org. Lett. 2011; 13: 1552
    CrossrefPubMed
  • 40 Coles SJ. Gale PA. Chem. Sci. 2012; 3: 683
    Crossref
  • 41 All reactions were conducted under an inert atmosphere unless specified otherwise. All commercially purchased materials and solvents were used without further purification unless specified otherwise. NMR spectra were recorded on a Varian VNMRS 500 (1H: 500 MHz, 13C: 126 MHz) spectrometer and prepared in deuterated solvents such as CDCl3 and DMSO-d 6. 1H and 13C chemical shifts were recorded in parts per million (ppm). Multiplicity of 1H NMR peaks are indicated by s – singlet, d – doublet, dd – doublets of doublets, t – triplet, pt – pseudo triplet, q – quartet, m – multiplet, and coupling constants are given in Hertz (Hz). Electrospray ionisation–high resolution mass spectra (ESI-HRMS) were obtained using a Bruker Daltonics Apex III where Apollo ESI was used as the ESI source. The molecular ion peaks [M]+ were recorded as mass to charge m/z ratio.
  • 42 LC–MS spectra were acquired using a Shimadzu LC-MS 2020, on a Gemini 5 µm C18 110 Å column and percentage purities were run over 30 min in water/acetonitrile with 0.1% formic acid (5 min at 5%, 5–95% over 20 min, 5 min at 95%) with the UV detector at 254 nm. Purifications were performed by flash chromatography on silica gel columns or C18 columns using a Combi flash RF 75 PSI, ISCO unit.General ProcedureTo a stirred solution of the appropriate 1,4-benzodiazepine or 1,3,4-benzotriazepine (0.030–1.00 mmol, 1 equiv) and diaryliodonium salt (0.033–1.10 mmol, 1.1 equiv) in DCE (5–10 mL) was added 25% w/w NH3 solution (aq. 5–10 mL), and the reaction mixture was stirred for 30 min (unless stated otherwise). Upon completion, the reaction mixture was diluted with dichloromethane (3 × 15 mL), and the layers were separated. Combined organic layers were dried (MgSO4), concentrated under reduced pressure, and purified by column chromatography, hexane/ethyl acetate (80:20 to 30:70).1-(4-Nitrophenyl)-5-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3a)The product was obtained as white solid (0.60 mmol scale, 170 mg, 96%). 1H NMR (500 MHz, CDCl3): δ = 8.27–8.21 (m, ArH, 2 H), 7.62 (dd, 3 J HH = 7.5, 1.5 Hz, ArH, 1 H), 7.40–7.35 (m, ArH, 3 H), 7.34–7.29 (m, ArH, 1 H), 6.82 (d, 3 JHH = 8.0 Hz, ArH, 1 H), 4.70 (d, 2 JHH = 10.5 Hz, COCH2, 1 H), 3.83 (d, 2 JHH = 10.5 Hz, COCH2, 1 H), 2.62 (s, CH3, 3 H). 13C NMR (126 MHz, CDCl3): δ = 170.1 (C=O), 168.1 (C=N), 146.7 (ArC), 146.0 (ArC), 140.8 (ArC), 131.4 (ArC), 131.3 (ArC), 128.7 (ArC × 2), 127.8 (ArC), 125.9 (ArC), 125.1 (ArC), 124.5 (ArC × 2), 56.6 (COCH2), 25.5 (CH3). ESI-HRMS: m/z calcd for C16H13N3O3 [+H]+: 296.1030; found: 296.1033. LC–MS purity (UV) = 100%, t R = 8.10 min.1-(4-Nitrophenyl)-5-(propan-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3b)The product was obtained as a white solid (0.52 mmol scale, 166 mg, 99%). 1H NMR (500 MHz, CDCl3): δ = 8.27–8.20 (m, ArH, 2 H), 7.59 (dd, 3 JHH = 7.5, 2.0 Hz, ArH, 1 H), 7.39–7.35 (m, ArH, 3 H), 7.34–7.30 (m, ArH, 1 H), 6.83 (dd, 3 JHH = 8.0, 1.5 Hz, ArH, 1 H), 4.72 (d, 2 JHH = 10.5 Hz, COCH2, 1 H), 3.82 (d, 2 JHH = 10.5 Hz, COCH2, 1 H), 3.34–3.25 (m, 1 H), 1.35 (d, 3 JHH = 7.0 Hz, CNCHC2CH 6, 3 H), 1.11 (d, 3 JHH = 7.0 Hz, CNCHC2CH 6, 3 H). 13C NMR (126 MHz, CDCl3): δ = 176.9 (C=O), 168.7 (C=N), 146.7 (ArC), 145.9 (ArC), 141.5 (ArC), 131.6 (ArC), 130.9 (ArC), 128.3 (ArC × 2), 127.0 (ArC), 126.0 (ArC), 125.0 (ArC), 124.5 (ArC × 2), 56.5 (COCH2), 35.6 (CNCHC2H6), 22.0 (CNCHC 2H6), 19.2 (CNCHC2H6). ESI-HRMS: m/z calcd for C18H17N3O3 [+H]+: 324.1270; found: 324.1281. LC–MS purity (UV) = 96 %, t R = 18.73 min.1-(4-Nitrophenyl)-3-(propan-2-yl)-5-(propan-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3c)The product was obtained as white solid (0.25 mmol scale, 91 mg, 99%). 1H NMR (500 MHz) CDCl3: δ = 8.25–8.18 (m, ArH, 2 H), 7.61 (dd, 3 JHH = 8.0, 1.5 Hz, ArH, 1H), 7.39–7.24 (m, ArH, 4 H), 6.85 (dd, J = 8.0, 1.5 Hz, ArH, 1 H), 3.27 (hept, 3 JHH = 7.0 Hz, CNCHCH3CH3, 1 H), 3.12 (d, 3 JHH = 9.5 Hz, COCHCHC2H6, 1 H), 2.72–2.61 (m, COCHCHC2H6, 1 H), 1.33 (d, 3 JHH = 7.0 Hz, CNCHC2 H 6, 3 H), 1.07 (d, 3 JHH = 7.0 Hz, CNCHC2CH 6, 3 H), 1.05–1.02 (m, COCHCHC2 H 6, 6 H). 13C NMR (126 MHz, CDCl3): δ = 173.9 (C=O), 168.3 (C=N), 147.4 (ArC), 145.7 (ArC), 141.1 (ArC), 131.9 (ArC), 130.6 (ArC), 128.4 (ArC × 2), 126.8 (ArC), 125.7 (ArC), 125.1 (ArC), 124.4 (ArC × 2), 69.3 (COCHCHC2H6), 35.5 (CNCHCH3CH3), 22.2 (COCHCHC2H6), 21.9 (CNCHC 2H6), 20.1, (CNCHC 2H6) 19.3 (COCHCHC 2H6), 18.7 (COCHCHC 2H6). ESI-HRMS: m/z calcd for C21H23N3O3 [+H]+: 366.1812; found: 366.1816. LC–MS purity (UV) = 95%, t R = 23.47 min.1-(4-Nitrophenyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3d)The product was obtained as white solid (0.60 mmol scale, 176 mg, 82%). 1H NMR (500 MHz, CDCl3): δ = 8.30–8.23 (m, ArH, 2 H), 7.77–7.71 (m, ArH, 2 H), 7.55–7.51 (m, ArH, 1 H), 7.49–7.45 (m, ArH, 3 H), 7.45–7.41 (m, ArH, 3 H), 7.29 (d, 3 JHH = 8.0 Hz, ArH, 1 H), 6.94 (d, 3 JHH = 8.0 Hz, ArH, 1 H), 4.96 (d, 2 JHH = 10.5 Hz, COCH 2, 1 H), 4.03 (d, 2 JHH = 10.5 Hz, COCH 2, 1 H). 13C NMR (126 MHz, CDCl3): δ = 170.3 (C=O), 168.3 (C=N), 146.7 (ArC), 146.0 (ArC), 142.7 (ArC), 138.4 (ArC), 131.4 (ArC), 130.8 (ArC), 130.4 (ArC), 130.3 (ArC), 129.4 (ArC × 2), 128.5 (ArC × 2), 128.4 (ArC × 2), 125.4 (ArC), 125.0 (ArC), 124.5 (ArC × 2), 57.4 (COCH2). ESI-HRMS: m/z calcd for C21H15N3O3 [+H]+: 358.1186; found: 358.1187. LC–MS purity (UV) = 95%, t R = 18.35 min.1-(4-Nitrophenyl)-3-benzyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3e)The product was obtained as white solid (0.40 mmol scale, 140 mg, 78%). 1H NMR (500 MHz, CDCl3): δ = 8.27–8.21 (m, ArH, 2 H), 7.67 (d, 3 JHH = 7.5 Hz, ArH, 2 H), 7.52–7.48 (m, 1 H), 7.47–7.43 (m, ArH, 2 H), 7.41–7.37 (m, ArH, 5 H), 7.36–7.30 (m, ArH, 3 H), 7.25–7.21 (m, ArH, 2 H), 6.90 (d, 3 JHH = 8.0 Hz, ArH, 1 H), 4.01 (dd, J = 7.5, 6.0 Hz, COCHCH2, 1 H), 3.68 (dd, 2,3 JHH = 14.0, 6.0 Hz, COCHCH 2, 1 H), 3.62 (dd, 2,3 JHH = 14.0, 7.5 Hz, COCHCH 2, 1 H). 13C NMR (126 MHz, CDCl3): δ = 168.8 (C=O), 168.5 (C=N), 147.1 (ArC), 145.9 (ArC), 142.1 (ArC), 138.9 (ArC), 138.4 (ArC), 131.5 (ArC), 130.8 (ArC), 130.5 (ArC), 130.3 (ArC), 130.0 (ArC × 2), 129.5 (ArC × 2), 128.6 (ArC × 2), 128.5 (ArC × 2), 128.3 (ArC × 2), 126.3 (ArC), 125.3 (ArC), 125.1 (ArC), 124.5 (ArC × 2), 65.6 (COCHCH2), 37.9 (COCHCH2). ESI-HRMS: m/z calcd for C28H21N3O3 [+H]+: 448.1656; found: 448.1669. LC–MS purity (UV) = 99 %, t R = 20.81 min.7-Chloro-1-(4-nitrophenyl)-3-benzyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3f)The product was obtained as white solid (0.15 mmol scale, 54 mg, 75%). 1H NMR (500 MHz, CDCl3): δ = 8.26 (d, 3 JHH = 8.5 Hz, ArH, 2 H), 7.66 (d, 3 JHH = 7.5 Hz, ArH, 2 H), 7.57–7.50 (m, ArH, 1 H), 7.51–7.44 (m, ArH, 2 H), 7.42–7.36 (m, ArH, 3 H), 7.34–7.30 (m, ArH, 2 H), 7.26 (s, ArH, 3 H), 7.17 (d, J = 8.7 Hz, ArH, 1 H), 6.85 (d, 3 JHH = 8.5 Hz, ArH, 1 H), 3.99 (dd, J = 7.5, 6.0 Hz, COCHCH2, 1 H), 3.70–3.57 (m, COCHCH 2, 2 H). 13C NMR (126 MHz, CDCl3): δ = 168.4, (C=O), 167.2 (C=N), 146.6 (ArC), 146.1 (ArC), 140.6 (ArC), 138.6 (ArC), 137.7 (ArC), 131.7 (ArC), 131.1 (ArC), 129.9 (ArC × 2), 129.8 (ArC), 129.5 (ArC × 2), 128.7 (ArC × 2), 128.6 (ArC × 2), 128.3 (ArC × 2), 126.5 (ArC), 126.4 (ArC), 126.2 (ArC), 124.6 (ArC × 2), 119.3 (ArC) 65.8 (COCHCH2), 37.9 (COCHCH2). ESI-HRMS: m/z calcd for C28H20ClN3O3 [+H]+: 482.1266; found: 482.1286. LC–MS purity (UV) = 95%, t R = 19.71 min. 1-(4-Nitrophenyl)-3-benzyl-5-(pyridine-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3g)The product was obtained as white solid (0.11 mmol scale, 38 mg, 77%). 1H NMR (500 MHz, CDCl3): δ = 8.67–8.62 (m, ArH, 1 H), 8.15 (d, 3 JHH = 8.0 Hz, ArH, 2 H), 8.18–8.12 (m, ArH, 1 H), 7.88–7.81 (m, ArH, 1 H), 7.44–7.42 (m, ArH, 2 H), 7.42–7.37 (m, ArH, 4 H), 7.35–7.26 (m, ArH, 3 H), 7.25–7.21 (m, ArH, 2 H), 6.89 (d, 3 JHH = 8.0 Hz, ArH, 1 H), 4.10 (dd, 3 JHH = 8.0, 6.0 Hz, COCHCH2, 1 H), 3.70 (dd, 2,3 JHH = 14.0, 7.0 Hz, COCHCH 2, 1 H), 3.62 (dd, 2,3 JHH = 14.0, 7.5 Hz, COCHCH 2, 1 H). 13C NMR (126 MHz, CDCl3): δ = 168.6 (C=O), 167.6 (C=N), 155.9 (ArC), 148.7 (ArC), 147.1 (ArC), 145.9 (ArC), 141.9 (ArC), 138.9 (ArC), 136.8 (ArC), 131.4 (ArC), 130.8 (ArC), 129.9 (ArC × 2), 128.8 (ArC × 2), 128.3 (ArC × 2), 126.3 (ArC), 125.2 (ArC), 125.1 (ArC), 124.8 (ArC × 2), 124.4 (ArC × 2), 123.8 (ArC), 65.8 (COCHCH2), 37.8 (COCHCH2). ESI-HRMS: m/z calcd for C27H20N4O3 [+H]+: 449.1608; found: 449.1617. LC–MS purity (UV) = 99%, t R = 20.81 min.1-(4-Nitrophenyl)-3-benzyl-5-(2′-fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3h)The product was obtained as white solid (0.03 mmol scale, 11 mg, 70%). 1H NMR (500 MHz, CDCl3): δ = 8.14 (d, 3 JHH = 8.5 Hz, ArH, 2 H), 7.57–7.52 (m, ArH, 1 H), 7.51–7.45 (m, ArH, 1 H), 7.42 (d, 3 JHH = 7.5 Hz, ArH, 1 H), 7.38 (d, 3 JHH = 7.5 Hz, ArH, 1 H), 7.32–7.27 (m, ArH, 7 H), 7.26–7.19 (m, ArH, 2 H), 7.15–7.09 (m, ArH, 1 H), 7.06 (d, 3 JHH = 7.5 Hz, ArH, 1 H), 7.00–6.93 (m, ArH, 3 H), 6.65 (d, 3 JHH = 8.5 Hz, ArH, 1 H), 3.80 (dd, 3 JHH = 8.0, 5.5 Hz, COCHCH2, 1 H), 3.69 (d, 3 JHH = 8.0 Hz, COCHCH 2, 1 H), 3.66 (d, 3 JHH = 8.0 Hz, COCHCH 2, 1 H). 13C NMR (126 MHz, CDCl3): δ = 169.5 (C=O), 167.9 (C=N), 159.2 (d, 1 J FC = 247.5 Hz, ArC) 147.1 (ArC), 145.7 (ArC), 141.5 (ArC), 138.8 (ArC), 138.7 (ArC), 135.7 (ArC), 132.0 (d, 3 J FC = 3.5 Hz, ArC), 131.6 (ArC), 131.4 (ArC), 130.8 (ArC), 130.3 (ArC), 129.9 (ArC x 2), 129.8 (ArC), 129.5 (ArC), 129.2 (ArC), 128.9 (d, 3 J FC = 8.0 Hz, ArC), 128.5 (ArC × 2), 128.3 (ArC × 2), 128.1 (ArC), 126.3 (ArC), 125.2 (ArC), 124.8 (ArC), 124.5 (d, 4 J FC = 3.5 Hz, ArC), 124.2 (ArC x 2), 115.4 5 (d, 2 J FC = 22.0 Hz, ArC) 66.0 (COCHCH2), 37.8 (COCHCH2). ESI-HRMS: m/z calcd for C34H24N3O3 [+H]+: 542.1874; found: 542.1881. LC–MS purity (UV) = 93%, t R = 23.27 min.1-(2,4,6-Trimethylphenyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3i)The reaction was run for 8 h. The product was obtained as white solid (1.00 mmol scale, 181 mg, 51%). 1H NMR (500 MHz, DMSO-d 6): δ = 7.60–7.57 (m, ArH, 2 H), 7.54–7.46 (m, ArH, 4 H), 7.32 (d, 3 JHH = 8.0 Hz, ArH, 1 H), 7.27–7.23 (m, ArH, 1 H), 7.10–7.07 (m, ArH, 1 H), 6.88 (s, ArH, 1 H), 6.78 (d, 3 JHH = 8.0, 1.1 Hz, ArH, 1 H), 4.70 (d, 2 JHH = 10.0 Hz, COCH 2,1 H), 4.04 (d, 2 JHH = 10.0 Hz, COCH 2, 1 H), 2.26 (s, CH3, 3 H), 2.24 (s, CH3, 3 H), 1.61 (s, CH3, 3 H). 13C NMR (126 MHz, DMSO-d 6): δ = 170.3 (C=O), 167.5 (C=N), 142.2 (ArC), 138.9 (ArC), 137.9 (ArC), 137.0 (ArC), 136.2 (ArC), 134.7 (ArC), 132.3 (ArC), 130.9 (ArC), 130.0 (ArC × 2), 129.6 (ArC × 2), 129.5 (ArC), 128.9 (ArC × 2), 128.7 (ArC), 124.4 (ArC), 122.1 (ArC), 57.3 (COCH2), 21.0 (CH3), 18.5(CH3), 17.5 (CH3). ESI-HRMS: m/z calcd for C24H22N2O [+H]+: 355.1805; found: 355.1804. LC–MS purity (UV) = 97%, t R = 21.13 min.1-(2-Bromophenyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3j)The reaction was run for 8 h. The product was obtained as white solid (1.00 mmol scale, 31 mg, 8%). 1H NMR (500 MHz, DMSO-d 6): δ = 7.84 (d, 3 JHH = 8.0 Hz, ArH, 1 H), 7.70 (d, 3 JHH = 8.0 Hz, ArH, 1 H), 7.66–7.59 (m, ArH, 4 H), 7.52–7.46 (m, ArH, 3 H), 7.41–7.37 (m, ArH, 1 H), 7.32 (dd, J = 7.8, 1.7 Hz, ArH, 1 H), 7.27 (d, 3 JHH = 7.0 Hz, ArH, 1 H), 6.92–6.83 (m, ArH, 1 H), 4.69 (d, 2 JHH = 10.5 Hz, COCH 2, 1 H), 4.01 (d, 2 JHH = 10.5 Hz, COCH 2, 1 H). 13C NMR (126 MHz, CDCl3): δ = 170.7 (C=O), 168.9 (C=N), 142.0 (ArC), 138.9 (ArC), 138.6 (ArC), 134.3 (ArC), 133.7 (ArC), 132.0 (ArC), 131.0 (ArC), 130.9 (ArC), 130.8 (ArC), 129.9 (ArC × 2), 129.8 (ArC), 129.1 (ArC), 128.8 (ArC × 2), 124.7 (ArC), 123.0 (ArC), 121.5 (ArC), 57.0 (COCH2). ESI-HRMS: m/z calcd for C21H15BrN2O [+H]+: 391.0441; found: 391.0457. LC–MS purity (UV) = 93%, t R = 15.23 min.1-(3′-Trifluoromethylphenyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3k)The reaction was run for 8 h. The product was obtained as white solid (0.50 mmol scale, 80 mg, 42%). 1H NMR (500 MHz, CDCl3): δ = 7.72 (d, 3 JHH = 7.5 Hz, ArH, 2 H), 7.60–7.55 (m, ArH, 2 H), 7.53 (d, 3 JHH = 8.5 Hz, ArH, 2 H), 7.49–7.45 (m, ArH, 2 H), 7.44–7.38 (m, ArH, 3 H), 7.25–7.20 (m, ArH, 1 H), 6.92 (d,3 JHH = 8.5 Hz, ArH, 1 H), 4.95 (d, 2 JHH = 10.5 Hz, COCH 2, 1 H), 4.02 (d, 2 JHH = 10.5 Hz, COCH 2, 1 H). 13C NMR (126 MHz, CDCl3): δ = 170.3 (C=O), 168.3 (C=N), 143.1 (ArC), 141.3 (ArC), 138.6 (ArC), 132.0 (q, 2 J FC = 29.9 Hz, ArC), 131.9 (ArC), 131.6 (ArC), 131.4 (ArC), 130.7 (ArC), 130.4 (ArC), 129.8 (ArC × 2), 129.5 (ArC), 128.5 (ArC × 2), 125.2 (q, 3 J FC = 3.5 Hz, ArC), 124.8 (ArC), 124.8 (ArC), 123.5 (q, 1 J FC = 273.0 Hz, ArC), 124.2 (q, 3 J FC = 3.5 Hz, ArC), 57.3 (COCH2). ESI-HRMS: m/z calcd for C22H15F3N2O [+H]+: 381.1209; found: 381.1208. LC–MS purity (UV) = 96%, t R = 21.35 min.1-Phenyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3l)The reaction was run for 8 h. The product was obtained as white solid (0.50 mmol scale, 14 mg, 9%). 1H NMR (500 MHz, CDCl3): δ = 7.72 (d, 3 JHH = 7.5 Hz, ArH, 2 H), 7.54–7.49 (m, ArH, 1 H), 7.47 (d, 3 JHH = 7.5 Hz, ArH, 2 H), 7.43–7.38 (m, ArH, 2 H), 7.37–7.30 (m, ArH, 2 H), 7.24–7.21 (m, ArH, 3 H), 7.20–7.16 (m, ArH, 1 H), 6.97 (d, 3 JHH = 8.5 Hz, ArH, 1 H), 4.96 (d, 2 JHH = 10.5 Hz, ArH, COCH 2, 1 H), 4.01 (d, 2 JHH = 10.5 Hz, COCH 2, 1 H). 13C NMR (126 MHz, CDCl3): δ = 170.7 (C=O), 168.3 (C=N), 146.5 (ArC), 143.3 (ArC), 140.7 (ArC), 138.6 (ArC), 131.3 (ArC), 130.7 (ArC), 130.3 (ArC), 129.6 (ArC × 2), 129.3 (ArC × 2), 128.4 (ArC × 2), 128.3 (ArC × 2), 127.5 (ArC), 124.7 (ArC), 124.2 (ArC), 57.2 (COCH2). ESI-HRMS: m/z calcd for C21H16N2O [+H]+: 313.1335; found: 313.1338. LC–MS purity (UV) = 90%, t R = 16.10 min.1-(4-Nitrophenyl)-3-(4-nitrophenyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (7)The product was obtained as white solid (0.60 mmol scale, 2 equiv of diaryliodonium triflate, 146 mg, 51%). 1H NMR (500 MHz, CDCl3): δ = 8.34–8.22 (m, ArH, 4 H), 7.85–7.79 (m, ArH, 2 H), 7.77–7.71 (m, ArH, 2 H), 7.74–7.57 (m, ArH, 3 H), 7.59–7.50 (m, ArH, 3 H), 7.41–7.32 (m, ArH, 2 H), 7.07–7.02 (m, ArH, 1 H). 13C NMR (126 MHz, CDCl3): δ = 166.0 (C=O), 158.3 (C=N), 149.1 (ArC), 146.7 (ArC), 145.6 (ArC), 144.1 (ArC), 143.3 (ArC), 135.0 (ArC), 132.6 (ArC), 131.5 (ArC), 129.9 (ArC), 129.6 (ArC), 129.5 (ArC × 2), 128.9 (ArC × 2), 126.8 (ArC × 2), 126.3 (ArC), 125.4 (ArC) 124.5 (ArC × 2), 124.3 (ArC × 2), 121.3 (ArC × 2). ESI-HRMS: m/z calcd for C26H17N5O5 [+H]+: 480.1230; found: 480.1245. LC–MS purity (UV) = 95%, t R = 18.35 min.1,1′-Oxybis(4-nitrobenzene)To a solution of (4-nitrophenyl)phenyliodonium triflate (30 mg, 0.06 mmol) in DCE (1 mL) was added sodium hydroxide (aq., 1 mL) and stirred for 20 min at room temperature. Upon completion, the reaction was diluted with dichloromethane (5 mL × 3) and the layers were separated. Combined organic layers were dried (MgSO4) and concentrated under reduced pressure to afford the product as a white powder (7 mg, 43%). 1H NMR (500 MHz, CDCl3): δ = 8.33–8.27 (m, ArH, 4 H), 7.19–7.14 (m, ArH, 4 H).13C NMR (126 MHz, CDCl3): δ = 160.6 (ArC × 2), 144.2 (ArC × 2), 126.2 (ArC × 4), 119.3 (ArC × 4). ESI-HRMS: m/z calcd for C12H8N2O5 [+H]+: 261.0511; found: 261.0513.
  • 43 CCDC numbers 1560492–1560494 contain the supplementary crystallographic data for compounds 3a, 3h, 3i. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures.